In this manuscript titled “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis” [1], the authors analyzed over 18 million reports from the Food and Drug Administration (FDA) Adverse Event Reporting System, among which over 17,000 cases were identified to have increased possibility of thyroid hyperplasia and neoplasm when taking glucagon-like peptide-1 (GLP-1) receptor agonist (RA) monotherapy. This evidence concerns the gene GCG and neoplasm.